Sophrosyne Technologies raises $ 2 Mn seed funding from Bluehill.VC
Sophrosyne Technologies is building a high-precision, ultra-low-power, compact and affordable SoC to power the next generation of invasive and non-invasive wearable and medical devices. The company is also developing proprietary Edge AI and Cloud models for real-time health-risk prediction and prevention.
Bluehill.VC has decided to partner with Sophrosyne in this mission by committing $ 2 Mn in seed funding.
The company also received significant support from the government through the MeitY DLI grant.
Dr. Manish Srivastava, Co-founder & CEO, Sophrosyne thanked Bluehill.VC for backing a deep-tech, semiconductor-first approach to digital health, and leaders – Vinod (Vin) Dham , Manu Iyer , Sridhar Parthasarathy for their guidance and belief in what we’re building.
We’re also grateful to have received significant support from the government through the MeitY DLI grant, which reinforces the strategic importance of indigenous biomedical silicon for India and the global healthcare sector.
Special thanks to GIMS Centre for Medical Innovation who provided us with invaluable insights into real-world healthcare delivery challenges and Semiconductor Fabless Accelerator Lab (SFAL) for making broader semiconductor ecosystem accessible to us.
Sophrosyne Technologies is a fabless semiconductor startup founded with the vision of making advanced healthcare technologies accessible to the masses. Our proprietary SoC, built on an ultra-low-power, high precision architecture, empowers devices to deliver long-term, continuous, and highly reliable health monitoring. Layered with our Edge and cloud based AI algorithm stack, raw health vitals are transformed into real-time, holistic assessments that enable timely medical intervention. Our technology allows device manufacturers to create cutting-edge solutions without disrupting their existing system architecture, accelerating time-to-market while keeping products affordable.
